A view on

Innovating Drug Development and Manufacturing: How External Collaborations  Shape the Future of Biotherapeutics In this episode of A View On, we speak with Andrew Brown, R&D Director at Lonza’s Integrated Biologics, and Zara Asgharpour, Director of External Innovation in Integrated Biologics, about how evolving molecular formats and external innovation are transforming the way biotherapeutics are developed and manufactured. The world of biotherapeutics is in constant evolution, with new molecular formats, scientific insights, and strategic partnerships shaping the medicines of tomorrow. These increasingly complex biologics require new approaches in development and manufacturing, from developing advanced characterization methods to flexible, innovation-driven platforms. Traditionally, biomanufacturing relied on well-established monoclonal antibodies and incremental process improvements. Today, developers are increasingly bringing a far broader range of modalities into the pipeline, each with unique scientific and manufacturability challenges. Meeting these demands requires both internal expertise and collaboration with external innovators. Advances in technology and science are reshaping the design, production, and innovation of biomolecules, making agility, partnerships, and new technologies key to the development of modern biologics.